🧬 biology

A Probiotic-Derived Oxydifficidin from Bacillus subtilis Y4 Combines Direct Antibacterial Activity and Immunomodulatory Effects Against Multidrug-Resistant Acinetobacter baumannii Infection

This study identifies oxydifficidin, a probiotic-derived metabolite from *Bacillus subtilis* Y4, as a promising therapeutic agent that combats multidrug-resistant *Acinetobacter baumannii* infections through direct membrane-disrupting antibacterial activity and immunomodulatory effects that reduce lung inflammation and bacterial burden in immunosuppressed mice.

Original authors: Xinyuan Li, Haowen Yan, Jinyu Mou, JinYang Gu, Lili Guan, Jingrui Chen, Lingcong Kong, Hongxia Ma, Haipeng Zhang

Published 2026-07-03

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Xinyuan Li, Haowen Yan, Jinyu Mou, JinYang Gu, Lili Guan, Jingrui Chen, Lingcong Kong, Hongxia Ma, Haipeng Zhang

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Problem: The "Superbug" Locksmith

Imagine a very tough burglar named Acinetobacter baumannii. This burglar is notorious for breaking into hospitals and making people sick, especially those who are already weak. The scary part? This burglar has learned to pick almost every lock we have. Doctors have tried many different keys (antibiotics), but the burglar has changed its locks so many times that the keys no longer work. This is what scientists call "multidrug-resistant."

The New Key: A Tiny Soldier from the Soil

The researchers went to a very special place: the soil of Changbai Mountain in China. They were looking for a tiny, natural "soldier" that could fight this burglar. They found a friendly bacterium called Bacillus subtilis Y4.

Think of this friendly bacterium as a factory that produces a special, invisible weapon. The researchers extracted this weapon, which they named Oxydifficidin. It's like finding a master key that the burglar has never seen before.

How the Weapon Works: Three Ways of Attack

The paper explains that Oxydifficidin doesn't just use one trick; it attacks the burglar in three different ways at the same time:

Breaking the Walls (Membrane Disruption):
Imagine the burglar is inside a fortress with strong walls. Oxydifficidin acts like a sledgehammer. It smashes holes in the burglar's outer walls. Once the walls are broken, the burglar's important internal secrets (like DNA and proteins) start leaking out, and the burglar collapses.
- The paper found: The walls became leaky, the electrical charge inside the cell vanished (like a battery dying), and the burglar's insides spilled out.
Turning Up the Heat (Oxidative Stress):
Inside the burglar's fortress, there is usually a calm temperature. Oxydifficidin turns on a "chemical fire" inside the burglar, creating a buildup of toxic "smoke" called Reactive Oxygen Species (ROS). This internal chaos confuses and damages the burglar from the inside out.
Stopping the Fortresses (Biofilm Inhibition):
Burglars often build a sticky shield (a biofilm) over themselves to hide from police (antibiotics). Oxydifficidin stops them from building these shields in the first place, leaving them exposed and vulnerable.

Is It Safe? (The "No Friendly Fire" Test)

Before using a new weapon, you have to make sure it doesn't hurt the good guys (humans).

The Red Blood Cell Test: The researchers put the weapon in a pool of human red blood cells. The cells stayed safe and didn't burst.
The Mouse Test: They gave the weapon to mice. The mice didn't get sick, their organs (heart, liver, lungs) looked normal under a microscope, and they didn't show any signs of poisoning.
Conclusion: The weapon is strong against the burglar but gentle on the host.

The Rescue Mission: Saving the Sick Mice

The researchers created a scenario where mice were very weak (their immune systems were turned down) and infected with the super-burglar. This caused severe pneumonia (lung infection).

Without the weapon: The mice got very sick, their lungs were inflamed and damaged, and their bodies were flooded with "alarm signals" (inflammatory chemicals like TNF-α, IL-6, and IL-1β) that actually hurt the lungs more than the bacteria did.
With the weapon: When the researchers gave the mice Oxydifficidin:
- The number of burglars in the lungs dropped significantly.
- The lungs looked much healthier and less swollen.
- The "alarm signals" in the blood went down. The weapon didn't just kill the bacteria; it also helped calm the body's overreaction to the infection.

What the "Brain Scan" (Transcriptomics) Showed

The researchers looked at the "instruction manual" (genes) inside the mice's lungs to see what was happening.

They found that the infection caused the body to go into a panic mode, turning on too many immune alarms.
Oxydifficidin helped turn down these alarms. It regulated the body's communication systems (specifically pathways involving "cytokine receptors" and "retinol metabolism"), helping the body stop panicking and start healing.

The Bottom Line

This study discovered a new natural weapon, Oxydifficidin, made by a soil bacterium. It fights the "super-burglar" (Acinetobacter baumannii) by smashing its walls, creating internal chaos, and stopping it from hiding. Most importantly, it works well in living animals and helps calm the body's inflammation without causing harm. It is a promising new tool for fighting infections that current medicines can't stop.

Technical Summary: Oxydifficidin from Bacillus subtilis Y4 Against Multidrug-Resistant Acinetobacter baumannii

Problem Statement
Multidrug-resistant Acinetobacter baumannii (MDR-AB) represents a critical global health threat, particularly as a leading cause of nosocomial pneumonia in immunocompromised patients. The pathogen's ability to develop resistance through diverse mechanisms—including efflux pumps, antibiotic target mutations, and biofilm production—renders standard therapies, such as carbapenems, increasingly ineffective. There is an urgent need for novel antimicrobial agents with distinct mechanisms of action and low resistance potential.

Methodology
This study employed a multi-faceted approach to identify, characterize, and evaluate a novel antimicrobial agent:

Strain Isolation and Identification: An antagonistic strain (Y4) was isolated from soil samples in Changbai Mountain, China. It was identified as Bacillus subtilis via 16S rRNA gene sequencing.
Extraction and Purification: The antibacterial metabolite was extracted using n-butanol, purified via silica gel column chromatography, and further refined using reversed-phase high-performance liquid chromatography (RP-HPLC).
Structural Identification: The active compound was identified as oxydifficidin (a difficidin-family polyketide derivative) using LC-ESI-MS/MS, with a molecular weight of 559.28925 Da ( $C_{31}H_{44}O_7P$ ).
In Vitro Characterization:
- Activity: Minimum Inhibitory Concentration (MIC) assays were conducted against nine pathogenic bacteria.
- Stability: The compound's stability was tested under varying temperatures, pH levels, and enzymatic conditions.
- Mechanism of Action: A comprehensive panel of assays was used to assess membrane integrity (Scanning Electron Microscopy, propidium iodide uptake, NPN uptake), membrane potential (DiSC₃(5) probe), intracellular leakage (nucleic acid/protein leakage), reactive oxygen species (ROS) accumulation, and biofilm inhibition.
- Safety: Hemolytic activity and acute toxicity in mice were evaluated.
In Vivo Efficacy: An immunosuppressed mouse model of MDR-AB-induced acute pneumonia was established. Mice were treated with oxydifficidin (10 mg/kg, intranasal) and monitored for bacterial burden, lung pathology, and inflammatory markers.
Transcriptomic Analysis: RNA sequencing (RNA-seq) and qRT-PCR were performed on lung tissues to analyze host immune responses and differentially expressed genes (DEGs).

Key Results

Antibacterial Potency: Oxydifficidin exhibited broad-spectrum activity with a potent MIC of 16 µg/mL against MDR-AB. Time-kill assays demonstrated concentration-dependent bactericidal activity, with 4×MIC resulting in rapid and sustained bacterial killing.
Stability and Safety: The compound retained >85% activity at 60°C and >90% activity after 30 days at -80°C. It showed stability at neutral pH but reduced activity under alkaline conditions. Crucially, oxydifficidin displayed low hemolytic activity (<10% at 4×MIC) and no detectable acute toxicity or histopathological damage in major organs of treated mice.
Mechanistic Insights: Oxydifficidin exerts its effects through a multi-target mechanism:
- Membrane Disruption: It compromises both the outer and cytoplasmic membranes, leading to increased permeability, dissipation of membrane potential, and leakage of intracellular components.
- Oxidative Stress: Treatment induced a significant, concentration-dependent accumulation of intracellular ROS.
- Biofilm Inhibition: The compound significantly inhibited biofilm formation in MDR-AB.
Therapeutic Efficacy: In the pneumonia mouse model, oxydifficidin treatment reduced the pulmonary bacterial burden by 2.30 log₁₀ CFU/g compared to the infected model group. It significantly alleviated lung tissue damage (hyperemia and hemorrhage) and reduced body weight loss.
Immunomodulation: Treatment suppressed the expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) at both the protein and mRNA levels. Transcriptomic analysis revealed that oxydifficidin regulated immune-related pathways, specifically modulating the complement and coagulation cascades and cytokine–cytokine receptor interactions, thereby mitigating hyperinflammation without compromising essential host defense.

Significance and Claims
The authors claim this study is the first to conduct an in-depth investigation into the biological characteristics and in vitro and in vivo antimicrobial mechanisms of oxydifficidin specifically against Acinetobacter baumannii. The study positions oxydifficidin as a promising antimicrobial metabolite derived from B. subtilis Y4 that combines direct bactericidal activity with immunomodulatory effects.

The significance of the findings lies in the compound's dual capability: it directly targets bacterial membrane integrity and metabolic processes (inducing ROS and inhibiting biofilms) while simultaneously regulating the host immune response to prevent excessive inflammation. The authors conclude that oxydifficidin represents a potential lead candidate for developing novel therapeutics against multidrug-resistant bacterial infections, though they note that further research is required to clarify its precise molecular targets, pharmacokinetic properties, and resistance potential.